W. R. Berkley Q3 2024 Earnings Call Transcript

Quartr
Provided by Quartr
October 23, 2024

There are 13 speakers on the call.

Operator

Greetings. Welcome to the Align Third Quarter 20 24 Earnings Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded.

Operator

I will now turn the conference over to your host, Shirley Stacy with Align Technology. You may begin.

Speaker 1

Good afternoon, and thank you for joining us. I'm Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO and John Marietje, CFO. We issued Q3 2024 financial results today via Business Wire, which is available on our website at investor. Aligntech.com.

Speaker 1

Today's conference call is being audio webcast and will be archived on our website for approximately 1 month. As a reminder, the information provided and discussed today will include forward looking statements, including statements about Align's future events and product outlook. These forward looking statements are only predictions and involve risks and uncertainties that are described in more detail in our most recent periodic reports filed with the Securities and Exchange Commission available on our website and atsec.gov. Actual results may vary significantly and Align expressly assumes no obligation to update any forward looking statement. We've posted historical financial statements with corresponding reconciliations, including our GAAP to non GAAP reconciliation, if applicable, and our Q3 2024 conference call slides on our website under Quarterly Results.

Speaker 1

Please refer to these files for more detailed information. With that, I'll turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?

Speaker 2

Thanks, Shirley. Good afternoon, and thanks for joining us today. On our call today, I'll provide an overview of our Q3 results discuss a few highlights from our 2 operating segments, Systems and Services and Clear aligners. John will provide more detail on our Q3 financial performance and comment on views for the remainder of the year. Following that, I'll come back and summarize a few key points and open the call to questions.

Speaker 2

Overall, Q3 2024 results were mixed and reflect strong system services year over year revenue growth as well as good clear aligner volume in Asia Pacific, EMEA and Latin America regions, partially offset by declines in the United States. As recently reported by many analysts and third party research firms, the underlying dental market in the United States remains sluggish and our doctor customers cite similar trends. Q3 'twenty four revenues of $978,000,000 increased 1.8% year over year and Clearliner volumes of $617,000 were up 2.5% year over year. Despite strong growth from systems and services revenues, a record 87,000 4,000 87,000 doctor submitters, a record of 236,000 teens starting treatment driven by record teen case starts in China and a record 25,000 of DSP Invisalign touch up cases. Total revenues for Q3 were slightly below our Q3 revenue outlook, in part due to more pronounced seasonality for clear aligners than expected, as well as continued weak consumer sentiment and a soft dental market, especially in the United States.

Speaker 2

Q3 'twenty four non GAAP operating margin of 22.1 percent was better than expected and increased year over year compared to 21.8% in Q3 of 'twenty three. For clear aligners, Q3 volumes were up year over year and down slightly sequentially. Year over year volumes were driven by strong growth in APAC, especially China, as well as growth from the EMEA and Latin American regions. On a sequential basis, Clearliner volumes were down from Q2 reflecting more pronounced seasonality and soft dental markets in the U. S, offset somewhat by strength in APAC and Latin American regions.

Speaker 2

In the Teen and Growing Kids segment, a record 236,000 teens and younger patients started treatment with Invisalign clear aligners during the Q3 and an increase of 9.1% sequentially and up 6.7% year over year, reflecting growth across regions, especially from Invisalign First and the APAC and EMEA regions. In Q3, the number of doctors submitting teen or younger patient case starts was up over 6% year over year, led by continued strength from doctors treating young kids, also known as growing patients. During the quarter, we continue to commercialize the Invisalign Pallet Expander, Align's first direct 3 d printed orthodontic appliance. Q3 reflected steady momentum for doctors, submitters and shipments in the United States and Canada. We recently announced commercial availability in Singapore and we're excited to extend the availability of the transformative Invisalign pallet expander system to even more doctors and their patients in markets across the Asia Pacific region.

Speaker 2

We expect it to be available in other markets pending future applicable regulatory approvals. Non case revenues include our Vevera retainers, retention aligners ordered through our doctor subscription program or DSP, clinical training and education accessories and e commerce. In Q3, non case revenues were up year over year, primarily due to continued growth in retainers and the DSP program, including non Invisalign patients getting retainers. DSP includes Invisalign touch up cases up to 14 stages and is currently available in North America and certain countries in Europe. For Q3, total Invisalign DSP touch up cases were up nearly 30% year over year to more than 25,000 cases.

Speaker 2

Q3 'twenty four Clearliner volume from DSO customers increased sequentially and year over year reflecting growth across all regions. The DSO business in the United States continues to outpace our retail doctors, driven by our largest DSO partners, Smile Docs and Heartland Dental. We also had strong growth in iTero scanner sales from DSOs investing in their member practices and end to end digital workflows. QC was another strong quarter for our systems and services business and year over year revenue growth was up 15.6%, reflecting higher scanner ASPs and non systems revenues driven by Itero Illumina, wand upgrades, increased scanner rentals and certified pre owned or CPO leasing programs as well as increased services revenues partially offset by lower scanner volumes. On a sequential basis, Q3 systems and services revenues were down 2.9%, reflecting lower scanner ASPs and non systems revenues, particularly offset by higher scanner volumes.

Speaker 2

The Itera Luminas new multi direct capture technology replaces the confocal imaging technology in earlier models and has a 3x wider field of capture and a 50% smaller and 45% lighter wand, delivering faster scanning speed, higher accuracy, super visualization and a more comfortable scanning experience. Luminous currently available with orthodontic workflows as new standalone scanner or as a wand upgrade from the Itero Element 5D Plus scanner. Overall for Q3, we continue to be very pleased with the ongoing adoption of Itero Luminas scanner with ortho workflow and response from customers. We currently expect to begin a limited market release for the restorative software on the Itero Luminous scanner in Q1 2025, followed by full commercialization by the end of Q1. Today, we announced new Itero scanner products innovations to further enhance digital dentistry workflows and integrated treatment options in oral health, restorative and aesthetic treatment in general dentistry.

Speaker 2

Align oral healthcare suite with new comparison tools that aid in multimodality assessments and personalized oral health records and reports. Invisalign Outcomes Simulator, a pro and multiple treatment simulation to drive chairside patient education about treatment options and Itero Design Suite with intuitive design capabilities for in practice 3 d printing now commercially available in selected markets. We believe the iTero intraoral scanner innovations introduced today enable doctors to present a variety of treatment options to their patients, supporting chairside education and communications. That helps deliver a great patient experience and supports patients in making more informed choices about their dental treatment and consultation with their doctors. We're also pleased to share that Invisalign Japan was recently awarded the Golden Design Award for 2024 for the Itera Lumina intraoral scanner, making this the 2nd time we received this prestigious award in the past 2 years.

Speaker 2

The Good Design Award is globally known and recognized by domestic and international designers and is the only comprehensive evaluation and recommendation system of design in Japan. The award designation increases the recognition and reliability of awarded works in companies, promotes problem solving through design and focuses on the significance of design to people in society. Before I turn the call over to John, I want to comment on the employment actions we announced today resulting from a global reorganization and restructuring. As part of Align's 2025 annual operating plan process, we identified positions to be eliminated or transferred to other locations. These are difficult actions and valuable employees will leave the company.

Speaker 2

As part of this restructuring, Rajputapetty's position as EVP and MD Americas and Chief Marketing Officer has been eliminated and we will leave and he will leave in the Q4. We thank Raj for his contributions to Align over the past 5 plus years in leading our marketing and product innovation management as well as overseeing the APAC and Americas regions. We wish Raj well. I'm pleased to welcome Frank Quinn back to Align. He's a well established leader with a customer focus and proven track record in orthodontics and digital dentistry.

Speaker 2

Frank's deep experience, understanding and insights into what digital means for our doctor customers is key and he's excited to be rejoining Align. With that, I'll now turn the call over to John.

Speaker 3

Thanks, Joe. Now for our Q3 financial results. Total revenues for the Q3 were $977,900,000 down 4.9% from the prior quarter and up 1.8% from the corresponding quarter a year ago. On a constant currency basis, Q3 2024 revenues were not significantly impacted by foreign exchange sequentially and were unfavorably impacted by approximately $14,600,000 year over year or approximately 1.5%. For clear aligners, Q3 20 24 revenues of 786 $800,000 were down 5.4 percent sequentially, primarily from lower volume, higher discounts, product mix shift to lower priced products and geographic mix, partially offset by lower net revenue deferrals.

Speaker 3

Q3 clear aligner revenues were not significantly impacted by foreign exchange sequentially. Q3, twenty twenty four clear aligners per case shipment of $12.75 was lower by $20 on a sequential basis due to higher discounts, product and geographic mix, partially offset by lower net revenue deferrals. On a year over year basis, Q3 clear aligner revenues were down 1%, primarily from lower ASPs, reflecting the impact from unfavorable foreign exchange of $11,700,000 or approximately 1.5%, a 20% price reduction in the UK to offset a 2024 ruling by the UK tax authorities in Q1 of 2024 that requires a 20% VAT be applied to clear aligner sales in the UK, product mix shift to lower priced products, geographic mix and higher discounts. This decrease was partially offset by lower net deferrals and price increases along with higher volumes and higher non case revenues. Q3 'twenty four clear aligner per case shipment of $12.75 was down $45 on a year over year basis due to unfavorable foreign exchange of $18 impact of UK VAT of $12 product and geographic mix, higher discounts and partially offset by lower net revenue deferrals and price increases.

Speaker 3

Our Invisalign comprehensive 3 and 3 product is available in North America, EMEA and in certain markets across APAC. We are pleased with the continued adoption of the Invisalign comprehensive 3 and 3 product and anticipate adoption will continue. Comprehensive 3 and 3 provides doctors the flexibility they want while allowing us to recognize more revenue upfront, with deferred revenue being recognized over a shorter period compared to our traditional Invisalign comprehensive product, which in turn allows us to benefit from a more favorable gross margin. Clear aligner deferred revenues on the balance sheet decreased $6,200,000 or 0.5 percent sequentially and decreased $25,800,000 or 2% year over year and will be recognized as additional aligners are shipped under each sales contract. Q3 2024 Systems and Services revenue of $191,000,000 were down 2.9% sequentially, primarily due to lower ASP and decreased non system revenues mostly related to fewer upgrades, partially offset by higher scanner volumes.

Speaker 3

Q3 2024 systems and services revenue were up 15.6% year over year, primarily due to higher ASPs, increased non system revenues mostly related to upgrades and our leasing rental programs and higher services revenue, partially offset by lower scanner volumes. Q3 2024 Systems and Services revenues impact by foreign exchange was approximately flat sequentially. On a year over year basis, systems and services revenues were unfavorably impacted by foreign exchange of approximately $2,900,000 or approximately 1.5%. Systems and services deferred revenues on the balance sheet was down $1,500,000 or 0.7% sequentially and down $40,600,000 or 15.4 percent year over year, primarily due to the recognition of services revenue, which are recognized ratably over the service period. The decline in deferred revenues both sequentially and year over year primarily reflects the shorter duration of service contracts applicable to initial scanner purchases.

Speaker 3

Moving on to gross margin. 3rd quarter overall gross margin was 69.7%, down 0.5 points sequentially and up 0.7 points year over year. Overall gross margin was not significantly impacted by foreign exchange sequentially and was unfavorably impacted by approximately 0.4 points on a year over year basis. Clear aligner gross margin for the Q3 was 70.3 percent, down 0.5 points sequentially due primarily to lower ASPs and higher mix of additional liners, partially offset by lower manufacturing spend. Clear aligner gross margin for the Q3 was down 0.5 points year over year due primarily due to lower ASPs, partially offset by lower manufacturing spend.

Speaker 3

On a constant currency basis, Clear aligner gross margin was unfavorably impacted by foreign exchange by 0.4 points year over year. Systems and services gross margin for the Q3 was 67.5%, down 0.7 points sequentially, due primarily to mix, partially offset by lower manufacturing spend and freight costs. Systems and services gross margin for the Q3 was up 6.5 points year over year due primarily to higher ASPs, partially offset by higher service and freight costs. On a constant currency basis, systems and services gross margin was unfavorably impacted by foreign exchange by 0.5 points year over year. Q3 operating expenses were $519,500,000 down 9.7% sequentially and up 4.6% year over year.

Speaker 3

On a sequential basis, operating expenses were down $56,100,000 due primarily to non recurring legal settlements, advertising and marketing and employee compensation. Year over year operating expenses increased by $22,700,000 primarily due to employee compensation. On a non GAAP basis, excluding stock based compensation, amortization of acquired intangibles related to certain acquisitions, restructuring, legal settlements and other charges, operating expenses were $472,700,000 down 5.4 percent sequentially and up 3.1% year over year. Our 3rd quarter operating income of 162 point $3,000,000 resulted in an operating margin of 16.6 percent, up 2.3 points sequentially and down 0.7 points year over year. Operating margin was favorably impacted from foreign exchange of approximately 0.1 points sequentially and unfavorably impacted by 0.8 points sequentially and unfavorably impacted by 0.8 points year over year.

Speaker 3

On a non GAAP basis, which excludes stock based compensation, amortization of intangibles related to certain acquisitions, restructuring, legal settlements and other charges, operating margin for the Q3 was 22.1 percent, down 0.2 points sequentially and up 0.3 points year over year. Interest and other income and expense net for the Q3 was an income of $3,600,000 primarily due to foreign exchange compared to an expense of $3,200,000 in Q2 of 2024 and an expense of $4,200,000 in Q3 of 2023. The GAAP effective tax rate in the 3rd quarter was 30.1% compared to 32.9% in the 2nd quarter and 25.1% in the Q3 of the prior year. The 3rd quarter GAAP effective tax rate was lower than the 2nd quarter effective tax rate, primarily due to adjustments related to tax return filings, partially offset by a small increase in uncertain tax position reserves. The Q3 GAAP effective tax rate was higher in the Q3 than the Q3 effective tax rate in the prior year, primarily due to recognizing a one time benefit related to the application of tax guidance issued during the Q3 of the prior year.

Speaker 3

Our non GAAP effective tax rate in the 3rd quarter was 20%, which reflects our long term projected tax rate. The 3rd quarter net income per diluted share was $1.55 up sequentially $0.27 and down $0.03 compared to the prior year. Our EPS was favorably impacted due primarily due to foreign exchange by $0.03 on a sequential basis and unfavorably impacted by $0.08 on a year over year basis. On a non GAAP basis, net income per diluted share was $2.35 for the 3rd quarter, down $0.06 sequentially and up $0.21 year over year. Moving on to the balance sheet.

Speaker 3

As of September 30, 2024, cash and cash equivalents were $1,041,000,000 up sequentially $280,500,000 and down $197,100,000 year over year. Of our $1,041,900,000 balance, dollars 285,000,000 was held in the U. S. And $756,500,000 was held by our international entities. We have $500,000,000 available for repurchase of our common stock under our January 2023 repurchase program.

Speaker 3

Beginning in Q4 2024 and continued into Q1 2025, we expect to repurchase up to $275,000,000 of our common stock through either a combination of open market repurchases or an accelerated stock repurchase agreement. Q3 accounts receivable balance was $1,010,600,000 down sequentially. Our overall day sales outstanding was 93 days, up approximately 4 days sequentially and up approximately 8 days as compared to Q3 last year. Cash flow from operations for the Q3 was $263,700,000 Capital expenditures for the Q3 were $29,800,000 primarily related to investments in our manufacturing capacity and facilities. Free cash flow defined as cash flow from operations less capital expenditures amounted to $233,900,000 Turning to our 2024 outlook.

Speaker 3

Assuming no circumstances occur beyond our control, including foreign exchange, we expect the following business outlook for the 4th quarter. We expect Q4 2024 worldwide revenues to be in the range of $995,000,000 to 1,000,000,000,015,000,000 dollars We expect Q4 2024 Clear Aligner volume and ASPs to be slightly up sequentially. We expect Q4 2024 Systems and Services revenues to be up sequentially consistent with typical Q4 seasonality. We expect Q4 2020 4 GAAP operating margin to be slightly lower than 14%, primarily due to restructuring charges related to severance for impacted employees. We estimate these restructuring charges will impact Q4 20 24 GAAP operating margin by approximately 3 points.

Speaker 3

We anticipate Q4 20 24 non GAAP operating margin to be slightly up sequentially. For fiscal 2024, we expect investments in capital expenditures to be above $100,000,000 Capital expenditures primarily relate to building construction and improvements as well as manufacturing capacity in support of continued expansion. As we have said many times, we continually evaluate and evolve our business model to provide doctors with the best tools and resources that they need to help them treat their patients, while managing our operations responsibly. Today's restructuring action is designed to adjust our business to more closely align with the existing business environment. We expect the restructuring actions we announced today will give us margin accretion for full year in 2025 even as we scale up our next generation direct 3 d print and fabrication manufacturing.

Speaker 3

With that, I'll turn it back over to Joe for final comments. Joe?

Speaker 2

Thanks, John. In closing for Q3, I was pleased to report another strong systems and services quarter and I'm excited about our next generation Luminess scanner and its continued positive impact on our customers' digital workflow with ortho software today and restorative software expected to be released in Q1 of next year. Q3 was also strong for our Invisalign clear aligner business in the Asia Pacific, EMEA and Latin America regions. For those markets are our fastest growing regions and help to balance out performance in other geographies. We understand that operating environment is more challenging and we are adapting and driving our growth strategy despite continued weak consumer demand trends, especially in United States in a sluggish dental market.

Speaker 2

In the face of inflation, high interest rates, less patient traffic and longer conversion cycles, especially for adult patients, orthodontists and dentists are facing challenges in practice growth and profitability that impacts the way many of them approach orthodontic treatment. It is more important than ever that we differentiate our products and services and become the best partner for our customers by creating solutions that drive more patients to their practices, accelerates treatment conversion and improves their experience and bottom line. As the innovation leader in digital dentistry technology, it's our job to ensure we have the organizational structure, focus and rigor to help doctors realize the full potential of this opportunity by doing more to engage our doctor customers and support their practice growth and to help consumers and potential patients connect with these practices to get the smiles that they love. We continue to evaluate and evolve our business to provide doctors with the best tools and resources they deserve. Align is the leader in digital orthodontics and we are committed to supporting doctor customers and the future of digital innovation.

Speaker 2

We're committed to supporting doctor customers and the future of the digital innovation and are excited to next wave of growth drivers that we believe will revolutionize the orthodontic industry in scanning software and direct three d printing. We're in the midst of several key technology developments that are critical for the business. We will take the needed actions to get us through this, while at the same time investing in the key areas that we know will transform our industry and our business. The restructuring actions we announced today focus on ROI investments and activities that drive revenue and enable margin expansion, while making room for investments in critical future technologies, including scaling our direct three d printing operations. With that, I thank you for your time today.

Speaker 2

I look forward to updating you on our continued progress over the coming quarters. Now I'll turn the call back over to the operator for questions. Operator?

Operator

Thank you. Our first question comes from Brandon Vazquez with William Blair. You may proceed.

Speaker 4

Hi, everyone. Thanks for taking the question. I wanted to start on a little bit just a macro backdrop. Last year, the year over year comp also had a little bit of weakness in the September period, if I remember, in 2023. So things are a little bit worse now.

Speaker 4

I'm just curious if you can talk about did things get worse from last year, which was already a little bit of a little weak. And in case that doesn't make sense, the crux of the question is essentially just talk to us about where macro is going into year end. Is it stable? I think you guys have used that phrase before. Is it worsening?

Speaker 4

Just any thoughts you guys are seeing on end markets?

Speaker 2

Yes, Brandon, it's Joe. I'd say, 1st of all, 3rd quarter is always a tough quarter because of the discontinuities we have with Europe shutting down and different countries being on vacation at different times. So I wouldn't say that the Q3 this year was worse in some way than the Q3 last year. I'd just say that it was the kind of seasonality in the difficult market. What we try to call out, as you could see, is that the United States market seems to be one of our the most affected and it's really one of our largest markets too.

Speaker 2

And so that's been a challenge in that sense also. John, do you want to add anything?

Speaker 3

That's accurate.

Speaker 4

Okay. And then as my follow-up just quickly, as we look towards 2025, right, and if we just assume end markets are stable, right, let's say things remain stable, how should we think about what the top line on this business could do and what the P and L could look like in a year where things are stable, right? You guys are somewhat macro hindered right now. So is it a continuation of what we're seeing in 2024? Are there reasons to get a little bit more excited and accelerate the business?

Speaker 4

Any expectations around that would be helpful. Thank you.

Speaker 2

Hey, Udi. Joe again. I'd just say we'd like to see some increased consumer confidence obviously in the United States and just an economy that feels better to consumers. We feel that this is more of an external issue than it is an internal issue when you look at Align overall in our growth rates, particularly in the United States. And so any kind of increase in economic activity and increase in consumer confidence, we think would be really positive for our customers and then for Align in turn.

Speaker 1

Thanks, Brandon. Next question, please.

Operator

Thank you. Our next question comes from Jon Block with Stifel. You may proceed.

Speaker 2

Hey, Jon. Hey,

Speaker 5

Jon. Good afternoon, Joe. Joe, maybe just to start with you, and it sort of picks up on that last question. Anything to call out with the different results in the U. S.

Speaker 5

Versus international? In other words, I think I've got this right, but cases up 2.5% globally, but as you mentioned, down in the U. S. So is it just the consumer? Is there anything to focus on from a go to market strategy?

Speaker 5

Do we have to think about incremental competition that might be more acute in the U. S. Versus OUS? Just would love your thoughts on that dynamic.

Speaker 2

Yes, John, it's a good question. I'd say, it's mainly external when I look at it. I don't think there's been any dramatic changes from a competitive standpoint in the marketplace. But I look at our ortho channel and our dental channels, they're both challenged in the sense of patient throughput and their ability to close. I was just talking to some of our largest DSOs this morning and the comparison is similar.

Speaker 2

This is and these are the close rates at our customers are more difficult too. Its customers come in, we know they want teeth treatment, but they're not really confident in the sense of their ability to pay for it or wanting to pay for it right now in the economic situation. So I wouldn't call out anything externally from a competitive standpoint or whatever. This is more we feel is external economics and consumer confidence issue in the United States. But we see, John, the same thing in Europe, but Europe has been a little better and a little different because all those countries have different situations, but it's more pronounced in the United States because it's so large and so uniform in that sense.

Speaker 5

Got it. Okay, thanks. And then second question will be sort of a famous 2 parter. But John, just to start, I just want to be crystal clear, you guys are committing to overall op margin expansion in 2025, if that's correct, it will be somewhat neutered by the direct 3 d printing fabrication initiative. Maybe if you can verify that and then any thoughts on the top line that would just be first question or I'll call it Part A.

Speaker 5

And Part B Go ahead.

Speaker 3

Sorry. Go ahead, Gerry. I was going to give the op margin. The op margin, yes, we made the restructuring actions given us room so that we can get the year over year margin accretion while still investing in all the things that we've talked about with direct fab and 5 MinuteClintCheck and Lumina and so on. So we're going to continue making those investments.

Speaker 3

The restructuring gives us some room to show that margin accretion.

Speaker 5

Okay. And again, the other part of that question was any thoughts on the top line if you're committing to the OM expansion, what does that mean from a top line perspective? And the second one, Joe, just if I can pivot and if you can talk to some of the initiatives out there, in other words, it seems like cost goes off to a slow start per our checks. Do you need to be in the store? And then more recently, we picked up on a new financing initiative that it seems like you're rolling out.

Speaker 5

It sort of guarantees the case approval. Denials have been a problem. Where are you with that initiative? And when do you expect it to have a more sort of prominent impact on the overall P and L? Thanks, guys.

Speaker 2

Yes. Hey, John, I'd just kind of just frame your question. The first one like Costco. We've had some success in Costco, but it's nothing that's material for the business right now. But I think you have to look at that as we do internally.

Speaker 2

It's a brand strategy. We have the number one brand in the world. We're looking at different areas of how we can leverage that brand to try to encourage consumers more in the sense of entertaining Invisalign treatment. As far as financing, we know that customers right now are challenged in the sense that they do want a treatment from an orthodontic standpoint, but they're really challenged from a financial standpoint. And John and the team are doing all they can.

Speaker 2

And also our DSO, big DSO partners are doing what we can to offer the type of financing that would give consumers more confidence to move forward.

Speaker 3

And on overall revenue, John, we'll give more of an update as we get closer into 2025. But as we've said and as we've made the adjustments, we're committed to driving growth, investing where we can find that growth, balancing our investments on some of the new technologies that we have that we know will transform this business. So that's all at stake now and things that we're mindful of, but we'll give more of an update on 2025 as we get closer.

Speaker 5

Thank you. Yes, you're welcome, Chad.

Operator

Thank you. Our next question comes from Elizabeth Anderson with Evercore ISI. You may proceed.

Speaker 6

Hi, guys. I'm also going to try my hand at a 2 parter as well, since that's Azim. One, I mean, as you talk about the restructuring as your Frank coming back to the organization, I think you hinted at it a little bit. I know it's obviously a little bit early. So your sort of high level qualitative thoughts would be fine on this too.

Speaker 6

Like what do you mean when you're what are you sort of like what is he going to sort of drive? Or what do you is there sort of like an inflection that you're thinking about how he operates the business differently? And sort of as a corollary to that, like, I think you talked about getting closer to the consumer, if you could talk maybe about that portion of it? And then secondarily, it was nice to hear the positive commentary about China. So I'd love to hear a little bit more about that market and sort of how you're thinking about the consumer outlook for that market as well.

Speaker 6

Thank you.

Speaker 2

Elizabeth, it's Joe. On Frank coming back, Frank was had been in the business from 2013. I think he left us in 2022 for another type of venture. Look, this business is about it's about 3 things. 1 is relationships.

Speaker 2

This is not a transactional business. This is one where you want to have good relationships and good trust with doctors and Frank really brings that from a leadership standpoint. Secondly, as you would need a good understanding of the technology and types of programs that can help to drive growth. Frank is really an expert in that area. He's shown that over the years.

Speaker 2

When you look at our DSO program today, it's been really effective. Frank happened to put that together back when I first arrived back in 2015, 2016 and really made that happen. Thirdly is you need someone with scope in the sense of understands the industries, understands the competition, knows what really makes doctors make decisions and orthodontists and how they make decisions versus the general practitioners. Frank has all of that and he's a trusted commodity within the business. So we're excited to have him back.

Speaker 3

And then the last part of your question, Elizabeth, on China. We're pleased with China results, sold to more doctors, pleased with the utilization. It's a great teen season for us in China. We saw good adoption of various products, including Invisalign First and others where we saw good utilization there. So China for us from a teen standpoint especially played out really well for us.

Speaker 1

Thank you.

Speaker 5

You're welcome.

Operator

Thank you. Our next question comes from Jason Bednar with Piper Sandler. You may proceed.

Speaker 7

Hi, Jason. Hey there. Good afternoon. I'm going to come back and follow-up on one of John's questions. I know a lot of us have been trying to estimate the margin upside or the margin impact from 3 d printing over time, just given the cost benefits you can realize from the initiative.

Speaker 7

But the comment today here with the restructuring offsetting some of the maybe some of the investments you're making, it would seem like that this initiative may be dilutive to gross margins in 2025. So maybe just help us may be dilutive to gross margins in 2025. So maybe just help us bridge the thinking that you're making in these comments today, reconcile some of those comments and if you can quantify kind of the puts and takes?

Speaker 3

Yes. I'll take my best at this. So overall, we were talking off margin. We think that the restructure that we're making is going to be up margin accretive on a year over year basis despite all the investments. You're right, from a gross margin standpoint, as we scale things, the direct fab printing, while it gives us a lot of capability and a lot of benefits for our doctors, there is a higher cost initially until we start to scale that.

Speaker 3

But we're committed to that op margin accretion on a year over year basis for next year despite that. And then as we have new products that come and we know the doctors are going to love what we're bringing to market, that will scale up. And as that scales up, then that really drives the overall productivity that we will see on the gross margin side, primarily from the materials and the less material that we need to go into the product.

Speaker 7

All right, understood. And I guess maybe one follow-up to there and then another separate follow-up, but just any timeline on when we might see the gross margin benefits or expansion off of historical norms once that 3 d printing does scale? And then just with the teen season maybe now mostly complete, just what's your assessment of that part of the market, Joe, inside the U. S, outside the U. S?

Speaker 7

The data we see has been a bit more mixed between kind of the clear aligner and bracket and wire part of the markets the past several months. Your business has grown decently the past year and a half. So just do you have better visibility on this part of the market? I'm just trying to understand this again in the context of the broader comments you're making on the U. S.

Speaker 7

Being a little bit softer. Thanks.

Speaker 3

So Jason, this is John. I'll take the first part of your question on gross margin. Look, we've talked about it being like a 2 to 3 year journey to be able to help scale this up. I can say this, we're very pleased with the progress that we're making around resin and being able to scale that and get it at the right cost. So that's good progress there.

Speaker 3

As well as on the equipment side, we're making good progress around being able to scale up the actual manufacturing of this. But in terms of when you scale this and get it to a larger extent, it's really 2 to 3 years. But you will see some new products that we have on the direct fab showing up next year and in doctors' hands to give them those capabilities.

Speaker 2

And Jason, on the teen market, I mean, when you look at the international teen market, obviously, we had really good success in Asia in the quarter. We have really a terrific portfolio when you think about our Invisalign First product. Now we have Invisalign pilot expander. With that also, it's what we call mandibular advancement with occlusal blocks, which are used for Class IIs, usually for patients between 10 11 years old. So when you look at those preteen ages, we have a really good portfolio to line up in that sense.

Speaker 2

So I think you're seeing that come through with our sales overall. When you reflect back on the United States, obviously our orthodontic customers are really challenged and 80% on an average, 75% of what they do are teens. And some of the close rates on teens, just talking to some of the DSOs and different doctors that we have on the orthodontic side, the close rates are even tougher on the teen segment than what it's been in the past too. And so times like this where they're pressed for traffic and they're pressed for margin, they will reflect back the wires and brackets to support the profitability of their practice. We know that.

Speaker 2

We understand it. It's our job to communicate to consumers and to orthodontists what the benefits are, particularly this early treatment and what we can do. And so this is a doctor to doctor situation. But again, it's an external environment where consumers are concerned with their pocketbooks right now, and they're reluctant to make decisions and close at times. And obviously, the orthodontists are responding from an individual practice standpoint accordingly.

Speaker 7

All right. Very helpful. Thank you.

Operator

Thank you. Our next question comes from David Saxon with Needham and Company. You may proceed.

Speaker 7

Great. Good afternoon. Thanks for taking my questions. I'd like to start on iTero actually. I'd love to get some color around how we should think about iTero growth with the ongoing Illumina rollout, particularly with the restorative workflow coming out early next year, but then in the context of interest rates remaining high and then lapping comps from the initial ortho launch?

Speaker 2

Yes, David, I think you have to start with and I think I get the gist of your question. There's a lot of pressure on capital equipment sales in the marketplace given what we're talking about with

Speaker 8

customers being challenged in that way.

Speaker 2

I think what you have to do with the being challenged in that way. I think what you have to do with the Lumin and think about it, it's truly a brand new platform. It's not an iteration of old technology like the next phase of our older technology. It's something that's really new and it's captured doctors' attention. I think it's the size of our sales and how well we've done, particularly in a traditional Q3, it's a little bit slower.

Speaker 2

I think it surprised a lot of people. So I think this is a testimony to the technology we've brought forward and the uniqueness of that technology, why we've been able to be able to have those kinds of sales at this point in time. We're excited about the restorative coming on in the Q1. The team is making good progress on that. So overall, it's just a great foundation to grow from them.

Speaker 2

What's wonderful about that platform too is we'll iterate from that platform going forward in different areas that will really help us to diversify the product line and target certain applications in the future.

Speaker 3

And 2 things that really have helped iTero and kind of go through this, especially with the new product. And so it's really given us a lot of opportunity on other products that we sell within the Itero kind of family. So all the way from CPOs that we have certified pre owned all the way to the 5D. We actually sold a lot of 5Ds this past quarter. So that really helps us.

Speaker 3

And then the added part in a tougher economy, we're giving a lot more flexibility to doctors to kind of sell the way they want to buy. Some don't want to purchase outright because of the economic conditions and so on. So we see a lot more leasing or in other places we see more rental. And for us that's a great trade. It will get that recurring revenue off of those, the different selling options, but then it's great when a doctor uses iTero because we know they'll do use more Invisalign.

Speaker 7

Great. Thanks for that. And then on the U. S. Side, on the clear aligners, can you give more color on kind of where that weakness is actually coming from?

Speaker 7

Is it the ortho channel or is it with GPs? And then anywhere specifically from a portfolio perspective? Thanks so much.

Speaker 2

Yes. I mean, it's almost equal in both. We see pressure on the ortho side. I mean, if you look at any kind of industrial data right now as far as patients entering the dental industry right now, the GP space, it's challenged overall. So we see pressure in both of those areas for the same reasons we talked about before.

Speaker 9

Yes.

Speaker 1

Thanks, David. Next question, please.

Operator

Thank you. Our next question comes from Jeff Johnson with Baird. You may proceed.

Speaker 10

Hey, Jeff. Thank you. Hey, Joe. How are you? Good afternoon, guys.

Speaker 10

So Joe, let me ask one high level question and then maybe just a modeling question for John. But from a high level, your R and D was down 4% year over year this quarter. You're making the headcount reductions. CapEx at $100,000,000 is well below even the last couple of years, closer to $250,000,000 those years. You're talking about increasing the buyback margin improvement next year.

Speaker 10

All of these comments kind of just point to a more mature company and that's not a critique at all. I think that's where we all know you are and see where you are. So I guess my question is how does this change your management style, your management objectives over the next few years? Obviously, you came into this business really pushing the top line, but is there an evolution that's happened to go on with how you lead this company and lead this organization as well?

Speaker 2

Hey, Jeff, I think it's a really good question. I'd say, we're responding to the times here. Don't make it a reflection on what the opportunity of the company is at all. We're so under penetrated, not just in the United States or North America or whatever, but all over the world. And there's hundreds of millions of people that need to have their teeth straightened.

Speaker 2

And the only way you could ever do that in a broad sense is with digital orthodontics. So don't miss that point, Jeff. We are going through a spell right now. And what you see with the R and D down and CapEx and different things like that, CapEx is we're not putting on any more manufacturing right now. We have enough manufacturing and we're still bringing up our Poland plant, right?

Speaker 2

We're being responsible from a business leadership standpoint for our shareholders in this specific situation. But at the same time, Jeff, we're pouring a lot of money into 3 d printing, 5 Minute ClinCheck, next phases of alumina. All these things will really enter into just another growth cycle when this market starts to come back with brand new techno. This is the technology of the future if you really want to play in digital orthodontics. So what we're doing is funding that, being responsible to our shareholders, but not losing our enthusiasm and what we think our opportunities in the future.

Speaker 10

Yes. No, that's all fair. You are holding the sell side event or at least an investor event a week from Saturday. Would that be a time to evaluate though that LRP that 20% to 30% intermediate longer term top line growth expectation?

Speaker 2

I think until we get a better read on what the economy is going to do, Jeff, I think that 20 to 30 represents how we feel that market can grow in the future. But we have to have the right economic conditions, particularly in the biggest markets in the world like the United States that we participate

Speaker 10

in. Okay. And John, one modeling question, just when I listened to the ASPs, I think the quick math on that is, it sounds like between the VAT issue that should anniversary at the start of next year, just remind me if I've got the timing on that correct, but should anniversary at the start of next year, currency headwinds should be we'll see what the U. S. Dollar does post election year, but should be reasonably moderating from here.

Speaker 10

So I think ex currency and ex VAT, you had about a 1.1 percent down ASP year over year. 1, is that math correct? And 2, is that about what we should be thinking about as we head kind of into 2025 once VAT and hopefully FX normalizes a bit?

Speaker 3

You're right about FX hopefully normalizes, it's hard to predict. VAT does anniversary at the beginning of next year. And what we've said in the past that that ASVs would be flat to slightly down. So your percentage you're talking about is in that range.

Speaker 1

Thank you. Thanks, Jeff.

Operator

Thanks, Joe. Thank you. Our next question comes from Kevin Caliendo with UBS. You may proceed.

Speaker 2

Hi, Kevin.

Speaker 11

Hey. Thanks. Hi, Joe. Thanks for taking my question. This is maybe a little bit off, but just wondering if you guys have ever done this analysis in terms of thinking about the Venn diagram between people purchasing GLP-1s and people going and getting Invisalign treatments, because the costs for adults anyways might be close.

Speaker 11

And I'm just wondering if there's any if you guys have seen any correlation to maybe that's part of the weakness in the adult market as the shortages have since GLP ones have come down, are people maybe investing $5,000 that way as opposed to into clear aligners? Have you guys done that analysis or seen anything?

Speaker 2

I can't say that we've been overly quantified it, Kevin. We hear that a lot. There's a lot of medical device companies that kind of talk about that. That might be corollaries in the sense of what you're seeing with the GLP marketplace overall. I can't say that it's not a factor because it's obviously a high expense and something that's kind of on an annual basis in line to what it would cost to do an Invisalign treatment.

Speaker 2

But I haven't wanted to lean into that as one of the drivers here. I think it's just overwhelmed by an economy right now where consumers don't have a lot of money in their pocket or confidence about what it's going to be in the future. And GLP might play a role in it, it might not. I think also you can look around the world also in some of the markets like Continental Europe that's not necessarily as affected by it as maybe United States is and I can't say I've seen that piece too. So there's an old saying that correlation doesn't mean causation, right?

Speaker 2

And so I would stay with that right now.

Speaker 11

Fair enough. That's helpful. And just I know you don't want to talk about 25%, but let's just think about the Q4 and sort of what you're implying for your guide in exiting the year sort of a midpoint of like 5%. Should we just sort of take that as a starting point, adjust for whatever we think the economy might do that might impact the adult side of the marketplace more? And then think about Lumina as an add on to that.

Speaker 11

I mean is that sort of how you're thinking about the business?

Speaker 3

Yes. I think we'll obviously give more as we get closer to this, Kevin. But I think, look, you come out of the year, that's probably a good starting point to be able to build off of that and say, look, what do you think is going to happen to the economy? We're going to know more maybe about interest rates and election and other things will kind of come about and we'll have a better view of that. But I think it's a good starting point as you think about next year, you're going to add in some of the things that we've talked about with, aluminum restorative and other things and then build off of that.

Speaker 3

But we'll give more details as we get closer obviously.

Speaker 11

Appreciate it guys. Thank you.

Speaker 10

Yes, thanks, Kyle.

Operator

Thank you. Our next question comes from Michael Cherny with Leerink Partners. You may proceed.

Speaker 8

Hi, good afternoon. Maybe just one, following up on a question earlier on the some of the 3 d printing work in the fab related products that you're going to be pushing out. As you think about the potential for introduction to those products, how are you thinking given that this is a bit of a obviously different manufacturing approach that you've taken before, about what the rollout will look like? Will it look any different in terms of the types of beta customers that you're going to be pursuing? How should we think about tracking, I mean tracking is not the right word, but making sure that you're hitting on the right customer experience, the right overlap, the right introduction process as you get what obviously could be a very scalable set of products, set of new opportunities at the market.

Speaker 2

Hey, Michael, it's Joe. Just taking your question is, as you think about it, when you think of what we do today, when you vacuum form, obviously, you lose a huge amount of opportunity to differentiate the geometry of that particular product and how it can help a doctor. The one sector of our business that would I think will appreciate this the most will be the orthodontic community that do a lot of Class IIs, difficult cases, young teens and we'll be able to produce products that are more and more tailored to consumers in that specific condition than what we could do today. And so we would offer the product that way and we think it'd be very appealing to them. Secondly, from a general dentistry standpoint, it's a big part of our marketplace too.

Speaker 2

There's a lot that we can do to help them with this product line also. So I hope I'm answering your question, but the design freedom that we have here in the end and we have to prove it when you can use relatively different thicknesses, you can do different configurations for different kinds of clinical issues that a patient might have. We expect to have more predictability in the sense of how fast you can move those teeth and more certainty and how long those cases will take. And I think doctors are going to appreciate that, but I think as we're certain of that, patients will appreciate that too and we certainly would communicate that to patients.

Speaker 8

No, that certainly does help. And then maybe just one quick question that comes, it's not an attempt to go at 25 guidance specifically, but obviously the you've mentioned numerous times the UK VAT that's impacting ASPs internationally this year. Is there any outliers or one time dynamics that we should be thinking about or contemplating relative to next year, something that like the UK VAT or anything else that could factor into the modeling that's non normal?

Speaker 3

Michael, this is John. Nothing that we would say is non normal. I mean, the nice thing about the anniversary of the U. K. VAT is it does anniversary.

Speaker 3

Obviously, we're doing things to try to work with that government there to explain and ideally not have a VAT on our products because it affects what goes to doctors and how much they pay and then passing it on to potential patients. But there's nothing like that that we would see on the horizon as that type of impact.

Speaker 1

Thanks, Michael. Next question, please.

Operator

Thank you. Our next question comes from Erin Wright with Morgan Stanley. You may proceed.

Speaker 9

Great. Thanks. Can I speak a little bit more on just the nature of the restructuring outside of the executive change today? I guess the timeline, scope, magnitude and anything that you can give us in terms of quantifying that benefit from a profit perspective into 2025 and what that translates into just broadly speaking, but also just what how this kind of came about in terms of what's on the table, what were your changes that you were thinking about in terms of the business outlook or backdrop that really changed in your view since it's been a sluggish kind of consumer backdrop for some time. Now I guess what else has changed?

Speaker 9

Thanks.

Speaker 3

Yes. Aaron, I could try to give you kind of an overview of where things are at. Just as part of a normal AOP process, you're always evaluating where you're going to make investments, where you're going to fund it, how you're going to fund it and so on. So this is part of our process that we go through where we're planning out where we're going to end up for the year and what does it mean for next year and how do we grow and do all the things that we want to talk through. This type of restructuring, this is about 2x of what we did last year.

Speaker 3

Last year, we did about 350 or so, just over 300. This is close to 700 people. There's some restructuring charges. We talked about that this year. But really what it does and what I'll go back to what Joe was talking about.

Speaker 3

We want to be focused in on what we can drive as our business, what we can do from a growth platform standpoint, whether it's the direct fab, 5 Minute ClinCheck, Lumina Restorative, we want to fund those, but we've got to also show some margin accretion and we want to be margin accretive on a year over year basis. So we can fund what we need to fund to really be driving our business and we'll fund it based on some of these changes here, but it really set us up for a position to be able to show that margin accretion next year.

Speaker 9

Okay, great. And then as we head into the Q4, I guess, does your guidance assume a continuation of the same in terms of the sluggish environment in the U. S? Or does it have any sort of changes across other regions that you anticipate either continued acceleration or deterioration across other kind of markets or geographies here? Thanks.

Speaker 3

Yes, Aaron. It just kind of assumes what we've seen. I mean like as we pointed out U. S, North America not great, kind of assume the same. Other places we actually saw good improvement in parts of Asia, Latin America, Middle East, other places and we continue to invest and expect to grow in those areas.

Speaker 3

So like any forecast, you take the best information you have at the time. You try to translate to what that's going to mean for the upcoming quarter and that's what we did for Q4.

Speaker 1

Thanks, Aaron. Next question, please.

Operator

Thank you. Our next question comes from Mike Ryskin with Bank of America. You may proceed.

Speaker 12

Hey, thanks guys. Just a couple of cleanup follow-up questions. One, I think just kind of following up on what Aaron touched there and John you touched on this as well. 2 years in a row now and again part of that is just natural attrition, natural cleanup of the business. But should we expect this to be sort of the normal going forward in terms of the restructuring?

Speaker 12

You guys famously kind of held off on that for a while. And very famously during COVID, you actually reinvested and you refused to cut and others were cutting. So just help us think in terms of how we should factor that in going forward?

Speaker 2

Hey, comparing this time with COVID is a stretch, Michael, overall. When we didn't lay anybody off during COVID, our expectation was that that wouldn't last as long as it did. But fortunately, that was a decision to pay off well because when the market came back so strongly. Right now, we're looking at just a sustained economic malaise, I would call it, in the United States and we're responding accordingly. We haven't lost our enthusiasm and our belief in how this business can grow and this market potential of this business.

Speaker 2

What you're seeing in the restructuring is we're responding to external pressures that we see in being responsible from a business standpoint and being sure that we fund these key three technologies that we know will lead into the future from an overall digital orthodontic standpoint.

Speaker 3

And that's the key point of it now. It's being able to make space and have a budget to be able to fund these key technologies because we know that's going to drive the future and it's doing things that we know no one else can do, no other company can do what we're trying to do with this. So it's really important for us now to keep that focus through these budget changes and so on. It's what companies do to be able to push the future and do it in a responsible way where we could show margin accretion. We know we always talk about levers that we could pull or not pull.

Speaker 3

This is a part of it and it just comes about it on a more annual basis as you assess the current environment.

Speaker 12

Okay. And then quick cleanup, if I could, on the ASPs. You talked about earlier, I think in the Q and A, you touched on some of the factors that impacted you in the quarter and your thoughts about next year. But just on 4Q, I think you've guided up ASP sequentially, and you've had some of these mix dynamics, some of the discounting and FX for a number of quarters in a row. Just what are you seeing so far through October that's giving you confidence that you'll be able to reverse that because I think some of those headwinds don't fade till next year?

Speaker 3

Yes. Well, I think part of really all our advantage programs kind of go from they end at the end of June and then they reset as you come into that second half. So Q3 kind of took the Advantage changes. So that shows up in discount. So I don't expect that to continue.

Speaker 3

And then where you do have the benefit and in our case where Europe becomes a bigger part of our business in the Q4 and China and some of the other businesses become less, that's good from a mix standpoint. We have a higher ASP in Europe and a lower ASP in China. So whereas that mix hurt us from a country standpoint, in a lower ASP in the Q3, we actually get the benefit on that in the Q4 based on seasonality.

Speaker 12

Okay. That's helpful. Thanks.

Speaker 1

Thank you, Michael. Yes. Thanks, Mike.

Operator

Thank you. And we have reached the end of our Q and A session. I'll now turn the call back over to Shirley Stacy for closing remarks.

Speaker 1

Great. Thank you, operator, and thanks, everyone, for joining us on the call today. We look forward to speaking to you at upcoming financial conferences and for those of you who will see at the Invisalign Ortho Summit in Las Vegas next week. If you have any other questions, please feel free to contact Investor Relations, and have a great day.

Operator

Thank you. This concludes today's conference and you may disconnect your lines at this time. Thank you for your participation.

Powered by Quartr
Earnings Conference Call
W. R. Berkley Q3 2024
00:00 / 00:00